Multivariate analysis of posttransplantation outcomes
| . | Odds ratio of graft failure (95% CI)* . | Relative risk (95% CI)† . | P . |
|---|---|---|---|
| Graft failure | |||
| MSD | 1.0 | — | — |
| URD matched | 5.39 (1.92-15.1) | — | .001 |
| URD partially matched | 11.8 (4.12-33.8) | — | .0001 |
| Chronic phase | 1.0 | — | — |
| Accelerated/remission post blast phase | 1.49 (1.01-2.22) | — | .05 |
| Blast phase | 2.13 (1.10-4.10) | — | .02 |
| Acute GVH disease (III-IV) | |||
| MSD | — | 1.0 | — |
| URD matched | — | 1.31 (1.06-1.62) | .01 |
| URD partially matched | — | 1.83 (1.44-2.32) | .0001 |
| Chronic phase | — | 1.0 | — |
| Accelerated/remission post blast phase | — | 1.12 (0.97-1.30) | .12 |
| Blast phase | — | 1.29 (0.99-1.67) | .06 |
| Older donor age, per decade | — | 1.10 (1.03-1.18) | .005 |
| Time to transplantation more than 1 year | — | 1.24 (1.08-1.43) | .002 |
| Interferon therapy pre-BMT | — | 0.85 (0.75-0.97) | .02 |
| Chronic GVH disease | |||
| MSD | — | 1.0 | — |
| URD matched | — | 1.48 (1.26-1.74) | .0001 |
| URD partially matched | — | 1.50 (1.22-1.85) | .0001 |
| Chronic phase | — | 1.0 | — |
| Accelerated/remission post blast phase | — | 1.22 (1.06-1.41) | .006 |
| Blast phase | — | 1.47 (1.09-1.97) | .01 |
| Female donor | — | 1.21 (1.08-1.37) | .001 |
| Hematologic relapse | |||
| MSD | — | 1.0 | — |
| URD matched | — | 1.13 (0.77-1.64) | .53 |
| URD partially matched | — | 1.48 (0.95-2.30) | .09 |
| Chronic phase | — | 1.0 | — |
| Accelerated/remission post blast phase | — | 4.37 (3.26-5.85) | .0001 |
| Blast phase | — | 12.8 (8.53-19.1) | .0001 |
| Older recipient age | — | 1.13 (1.00-1.27) | .06 |
| Male donor | — | 1.47 (1.11-1.92) | .006 |
| . | Odds ratio of graft failure (95% CI)* . | Relative risk (95% CI)† . | P . |
|---|---|---|---|
| Graft failure | |||
| MSD | 1.0 | — | — |
| URD matched | 5.39 (1.92-15.1) | — | .001 |
| URD partially matched | 11.8 (4.12-33.8) | — | .0001 |
| Chronic phase | 1.0 | — | — |
| Accelerated/remission post blast phase | 1.49 (1.01-2.22) | — | .05 |
| Blast phase | 2.13 (1.10-4.10) | — | .02 |
| Acute GVH disease (III-IV) | |||
| MSD | — | 1.0 | — |
| URD matched | — | 1.31 (1.06-1.62) | .01 |
| URD partially matched | — | 1.83 (1.44-2.32) | .0001 |
| Chronic phase | — | 1.0 | — |
| Accelerated/remission post blast phase | — | 1.12 (0.97-1.30) | .12 |
| Blast phase | — | 1.29 (0.99-1.67) | .06 |
| Older donor age, per decade | — | 1.10 (1.03-1.18) | .005 |
| Time to transplantation more than 1 year | — | 1.24 (1.08-1.43) | .002 |
| Interferon therapy pre-BMT | — | 0.85 (0.75-0.97) | .02 |
| Chronic GVH disease | |||
| MSD | — | 1.0 | — |
| URD matched | — | 1.48 (1.26-1.74) | .0001 |
| URD partially matched | — | 1.50 (1.22-1.85) | .0001 |
| Chronic phase | — | 1.0 | — |
| Accelerated/remission post blast phase | — | 1.22 (1.06-1.41) | .006 |
| Blast phase | — | 1.47 (1.09-1.97) | .01 |
| Female donor | — | 1.21 (1.08-1.37) | .001 |
| Hematologic relapse | |||
| MSD | — | 1.0 | — |
| URD matched | — | 1.13 (0.77-1.64) | .53 |
| URD partially matched | — | 1.48 (0.95-2.30) | .09 |
| Chronic phase | — | 1.0 | — |
| Accelerated/remission post blast phase | — | 4.37 (3.26-5.85) | .0001 |
| Blast phase | — | 12.8 (8.53-19.1) | .0001 |
| Older recipient age | — | 1.13 (1.00-1.27) | .06 |
| Male donor | — | 1.47 (1.11-1.92) | .006 |
Multivariate logistic regression analysis of graft failure in patients surviving to day +22 (n = 2801). The odds ratio ± 95% confidence interval (CI) is shown.
Cox multivariate regression analyses showing the relative risk ± 95% CI of acute GVH disease, chronic GVH disease, and hematologic relapse.